中国经济第一城已悄然培育出又一个增长极。 近日，上海市科委向外界透露，上海生物医药产业规模持续增长，从2021年7617.14亿元增长至2024年 9847.02亿元，年均复合增长率8.94%；2025年上半年达5005.66亿元，预计今年将突破1万亿元。 这意味着，继电子信息、汽车、高端装备、软件和信息服务四大万亿级产业集群之后，上海正式迎来第 五个万亿级产业板块。 更值得关注的是，随着生物医药迈入万亿阵营，上海重点布局的人工智能、集成电路、生物医药三大先 导产业，正集体崛起为新的经济支柱。 数字背后，是一场产业生态的聚变。 如，上海生物医药产业不仅总体规模逼近万亿元，制造业环节同样表现惊艳。从2021年到2024年，制造 业产值从1712亿元增长至2011.67亿元，年均复合增长6.9%。 作为国内最早布局生物医药产业的城市之一，上海生物医药实力雄厚。根据《上海市生物医药产业发 展"十四五"规划》提出的目标，到2025年，上海将初步建成世界级生物医药产业集群核心承载地，包括 6个百亿元级产业园区，产业规模超1万亿元。 此外，创新药械的突破，最能体现一个地区的研发实力。 2021年至2025年8月，上海获批 ...

Core Insights - The Shanghai biopharmaceutical industry is projected to grow from 761.71 billion yuan in 2021 to 984.70 billion yuan by 2024, with an average annual growth rate of 8.94% [1] - The biopharmaceutical manufacturing output is expected to increase from 171.20 billion yuan in 2021 to 201.17 billion yuan in 2024, reflecting a compound annual growth rate of 6.9% [1] - By the end of 2024, Shanghai will have 2,183 biopharmaceutical enterprises, with 19 of the top 20 global pharmaceutical and medical device companies having established headquarters or centers in the city [1] Industry Growth and Development - Shanghai has been a pioneer in the biopharmaceutical sector since 1993, emphasizing modern biotechnology and pharmaceuticals as key high-tech industries [2] - The "14th Five-Year Plan" for Shanghai aims to double the scale of three leading industries, including biopharmaceuticals, with a total fund of 100 billion yuan allocated for these sectors [2] - The biopharmaceutical industry accounted for a significant portion of the 1.8 trillion yuan combined scale of Shanghai's three leading industries in the previous year [3] Innovation and Market Position - Shanghai has established a complete biopharmaceutical industry chain with over 80,000 related enterprises, leading the nation with 30 companies listed on the Sci-Tech Innovation Board [4] - In 2024, Shanghai approved 7 first-class innovative drugs and 15 third-class innovative medical devices, representing 17.5% and 32.6% of the national total, respectively [4] - The city also leads in overseas licensing transactions, with 15 projects exceeding 500 million USD, totaling 19.83 billion USD, marking a 30.5% year-on-year increase [4] Future Prospects - Shanghai is on the verge of surpassing the 1 trillion yuan mark in its biopharmaceutical industry, with plans to enhance the entire value chain from basic research to application [5] - The city aims to become a world-class biopharmaceutical innovation hub and industrial cluster, focusing on accelerating technological innovation and high-end industry leadership [5]

Group 1: Safety Development in Hubei - Hubei province has achieved significant progress in safety development during the "14th Five-Year Plan" period, with a focus on risk prevention, safety assurance, and stability maintenance [1] - The province has been recognized for its safety production performance, ranking 5th nationally in 2023 and 4th in 2024, with a continuous decline in major safety incidents over the past 51 months [1] - Natural disaster response has improved, with a 57.3% reduction in affected population, a 69.9% decrease in deaths and disappearances, and a 68.4% drop in direct economic losses compared to the "13th Five-Year Plan" period [1] Group 2: Emergency Management System - Hubei has established a comprehensive emergency management system characterized by unified command, rapid response, and collaborative efforts across various levels [2] - The province has made significant investments in disaster relief resources, ensuring that supplies can meet the basic needs of 500,000 disaster-affected individuals for three days [2] - Over the past five years, Hubei has addressed over 2.59 million safety hazards, focusing on major disaster factors such as fire and explosion risks [2] Group 3: Natural Disaster Prevention - Hubei has enhanced its natural disaster prevention capabilities by building a unified early warning platform and conducting comprehensive risk assessments for 21 types of disasters [3] - Key infrastructure improvements include the reinforcement of 120 large and medium-sized reservoirs and the construction of 4,409 kilometers of forest fire emergency roads [3] - The province has provided assistance to 9.644 million disaster-affected individuals and repaired over 16,000 damaged homes in the past five years [3] Group 4: Pharmaceutical Industry Growth - The number of pharmaceutical companies in Hubei has increased by 42% during the "14th Five-Year Plan" period, reflecting a robust growth in the sector [4] - Hubei's drug safety measures have led to the investigation of 24,700 cases of violations, with a 99% pass rate in drug quality inspections [4] - Public satisfaction regarding drug safety has reached 89.4%, indicating improved public confidence in medication safety [4] Group 5: Support for Pharmaceutical Development - Hubei has approved 13 Class I innovative drugs, ranking 6th nationally and 1st in Central China, with a total of 445 pharmaceutical production enterprises established [5] - The province has also seen a 58% increase in Class II and III medical device manufacturers, contributing to a thriving market for safe and effective medical products [5] - The number of retail pharmacies has grown by 37%, enhancing access to quality pharmaceutical products for the public [5]

北京商报讯(记者王寅浩实习记者宋雨盈)9月21日上午，国家药品监督管理局药品和医疗器械审评检查 京津冀分中心在北京经济技术开发区正式挂牌运行。记者了解到，京津冀分中心主要服务北京、天津、 河北、山东等区域，负责协助国家药品监督管理局药品审评中心、医疗器械技术审评中心、食品药品审 核查验中心，综合开展药品和医疗器械审评事前事中相关研发指导、咨询受理、审评沟通等技术服务， 承担相关注册核查、巡回检查等工作。 药品和医疗器械审评检查京津冀分中心相关负责人表示，京津冀分中心的成立是国家药监局深化审评审 批制度改革，鼓励药品医疗器械创新，促进区域医药产业高质量发展的重要举措。未来，一定会以此次 挂牌为新起点，充分利用区域内创新能力突出、人才资源汇集的优势，建立科学、高效的区域性药品医 疗器械审评检查工作体系，不断提升工作效率与质量，为推动区域一体化发展、服务区域医药产业创新 发展、保护公众健康贡献力量。 据悉，京津冀鲁已成为全国医药健康产业发展的重要区域，2021年以来，累计获批创新药34个，占全国 16.2%；获批第三类创新医疗（002173）器械68个，占全国25.7%。2024年医药工业营业收入8415亿 元，占 ...